Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral CR845 in CKD-Associated Pruritus
NCT03617536Phase 2Completed
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of difelikefalin in pruritus, sponsored by Cara Therapeutics, Inc.. Started Jul 2018; status: completed.
02
Drugs
difelikefalin
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT03617536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03617536.